The implementation of a mutual recognition agreement between two parties aims to promote a mutually beneficial relationship between the parties, such as trade.B. Such an MRA came into force in 1999 between the European Union and Australia, which allowed the recognition and recognition of the technical competences of other countries by their respective compliance assessment bodies. During a transitional period, the authorities assess each other`s pharmaceutical legislation, guidelines and regulatory systems under the agreement. Australia has a Mutual Recognition Agreement (MRA) with the European Community (EC) and the European Free Trade Association (EFTA), which includes Iceland, Liechtenstein and Norway. The MRA includes compliance assessments for veterinary products. In some cases, we may also recognize audit reports and final instructions from the relevant authorities who are members of the Inspection/Cooperation Agreement (external link) (PIC/S). This recognition is done on a case-by-case basis. The MRA with Israel is an agreement on the evaluation of compliance and acceptance of industrial products (ACAA). It is a specific type of MRI based on the alignment of the legal system and infrastructure of the country concerned with that of the EU. Trade agreements are trade agreements designed to facilitate market access and promote greater international harmonization of compliance standards while protecting consumer safety. These agreements benefit regulators by reducing dual controls in any other area, allowing for a greater focus on sites likely to be at higher risk and increased coverage of global supply chain inspections. Since different legal and regulatory requirements apply between MRA partners, the MRA does not create a direct equivalence between Australian and EU legislation.
On the contrary, the MRA allows mutual recognition of test results and other compliance assessment documents, including certifications. This means that the APVMA and the foreign regulator have entered into an agreement for the recognition of GMP compliance certificates, audit reports and/or manufacturing licenses. For some foreign manufacturers, this means that the APVMA will consider this type of information – from one of these regulators – as acceptable proof of their compliance with GMP. Australia and the United Kingdom (United Kingdom) have signed an MRA on compliance assessment, certificates and markings in anticipation of the UK`s exit from the European Union. This MRA also includes recognition of the medical device compliance assessment certification. We have a cooperation agreement with the FDA. We accept U.S. FDA evidence regarding GMP marketing authorization applications using the CV pathway, regardless of inspection procedure, as long as the inspection has been conducted with a comparable GMP standard. The table below contains the countries and regulatory authorities with which we currently have a Mutual Recognition Agreement (MRA) or an equivalent agreement/arrangement. The GMP terminal route for manufacturers controlled by these regulators depends on the fact that the inspection was carried out within or outside its borders: the TGA has concluded a number of international agreements and agreements with other countries and regulators to support international regulatory cooperation.
Some of these agreements and agreements allow us to use the inspections carried out by these regulators as part of the GMP release procedure instead of our own on-site inspection. The European Union (EU) has signed Mutual Recognition Agreements (MRA) with third-country authorities on the assessment of compliance of regulated products.